Protalix BioTherapeutics (Protalix BioTherapeutics) Days Payable : 38.30 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Days Payable?

Protalix BioTherapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $3.72 Mil. Protalix BioTherapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $8.86 Mil. Hence, Protalix BioTherapeutics's Days Payable for the three months ended in Dec. 2023 was 38.30.

The historical rank and industry rank for Protalix BioTherapeutics's Days Payable or its related term are showing as below:

PLX' s Days Payable Range Over the Past 10 Years
Min: 68.94 Med: 181.01 Max: 2633.21
Current: 68.94

During the past 13 years, Protalix BioTherapeutics's highest Days Payable was 2633.21. The lowest was 68.94. And the median was 181.01.

PLX's Days Payable is ranked worse than
66.25% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs PLX: 68.94

Protalix BioTherapeutics's Days Payable declined from Dec. 2022 (218.91) to Dec. 2023 (38.30). It may suggest that Protalix BioTherapeutics accelerated paying its suppliers.

Protalix BioTherapeutics Days Payable Historical Data

The historical data trend for Protalix BioTherapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Days Payable Chart

Protalix BioTherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

196.08

230.22

158.59

119.68

80.86

Protalix BioTherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															218.91	162.19	62.40	59.84	38.30

Competitive Comparison of Protalix BioTherapeutics's Days Payable

For the Biotechnology subindustry, Protalix BioTherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protalix BioTherapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Days Payable falls into.

Protalix BioTherapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Protalix BioTherapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (5.862	+	4.32)	/	2 )	/	22.982	*	365
=	5.091					/	22.982	*	365
=	80.86

Protalix BioTherapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (3.114	+	4.32)	/	2 )	/	8.856	*	365 / 4
=	3.717					/	8.856	*	365 / 4
=	38.30

Protalix BioTherapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

PBDA:Germany

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Executives

Dror Bashan	director, officer: President and CEO	2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben	director	2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin	officer: Sr. VP and CFO	C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos	officer: Sr. VP, Operations	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon	officer: Vice President, R&D	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld	director	6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot	director	6225 NEIL ROAD, RENO NV 89511
Pol F Boudes	director	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor	officer: President & CEO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100